Teva Pharmaceutical and Biolojic Partner to Advance Innovative Antibody Treatment

Teva Pharmaceutical and Biolojic Design have established a license deal for the progression of BD9, a novel antibody-focused treatment that targets asthma and eczema. 

Teva will be granted sole licensing to research, produce, and market BD9 worldwide. 

An initial fee as well as subsequent payments will be granted to Biolojic if preliminary research, clinical, regulatory, and economic targets are met. 

Richard Francis, the leading chief of Teva Pharmaceutical, commented, “BD9 can tune itself to the specific underlying conditions of the disease and potentially help more patients who do not respond to current therapies and improve outcomes for existing responders, thus addressing a large unmet need.” 

Yanay Ofran, the head executive of Biolojic Design, added, “The potential therapy we designed for atopic dermatitis and asthma is another example of how AI can revolutionise drug development.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.